



ASX ANNOUNCEMENT

6 JUNE 2018

CANN GROUP R&D EXPANSION AT LA TROBE UNIVERSITY

- **Strengthened relationship to boost Cann's capabilities across plants genetics, breeding and cultivation**
- **Cann receives imported genetic strains from Canadian partners**
- **First of four Aurora oil products received in Australia and now available via Cann**

6 June 2018 – Cann Group Limited (ASX: CAN) will expand its research and development operations with La Trobe University after the signing of a memorandum of understanding (MOU) that strengthens the relationship between the parties.

The MOU is a precursor to a potential strategic relationship agreement (SRA) whereby Cann and La Trobe can enhance its capabilities across research, teaching and knowledge related to the medicinal cannabis industry.

Cann's corporate headquarters at La Trobe also continues to expand in line with the growth of the company.

La Trobe University conducts pioneering research in medicinal agricultural and biomedical sciences, sharing various goals and research objectives with Cann.

Cann Group CEO Peter Crock believes the deeper relationship with La Trobe will strengthen Cann's own capabilities in plant genetics, breeding, cultivation, extraction and analysis, while building a pipeline for clinical trials.

"We see this as a key development in advancing the medicinal cannabis industry in Australia, and most importantly, getting the right products to patients in need."

La Trobe University Deputy Vice-Chancellor (Research) Professor Keith Nugent said: "La Trobe's research strengths and capabilities in agricultural and biomedical sciences complement those of Cann Group.

"The outcome of this strengthened research and industry collaboration will not only provide economic benefits, but has the potential to improve the lives of thousands of people – our research into medicinal cannabis may help develop a body of evidence that could lead to treatments for a range of medical conditions including the management of chronic pain."

Cann Group will communicate further developments under the MOU to the market in due course.

Imported genetics one step closer

Cann Group is pleased to announce a number of tissue culture varieties from its Canadian partners Aurora Cannabis and Anandia Labs have now been received into Australia and are undergoing treatment and assessment at the governments quarantine facility. It will be several months before the genetic material is released from quarantine.

These new genetic strains will be used to further develop Cann's cultivation and breeding activities and enable the Company to establish a genetics bank. This will be key in allowing Cann to progress its research on the suitability of genetic strains for various therapeutic applications.

In addition to receipt of the tissue culture, Cann has today taken delivery of the first of four cannabis oil products developed by Aurora Cannabis that will be made available to Australian patients seeking access to medicinal cannabis via the Special Access Scheme or Authorised Prescriber Scheme.

For further information please contact:

Peter Crock
Cann Group Limited
+61 (0) 3 9095 7088
contact@canngrouponlimited.com

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia and internationally. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada's largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.9% shareholding.